



Consumer										
U.S.	\$ 1,370	1,285	6.6 %	6.6	-	\$ 4,282	4,186	2.3 %	2.3	-
International	2,045	2,071	(1.3)	3.7	(5.0)	6,035	5,876	2.7	1.6	1.1
	3,415	3,356	1.8	4.9	(3.1)	10,317	10,062	2.5	1.9	0.6
Pharmaceutical										
U.S.	6,097	5,816	4.8	4.8	-	17,350	15,698	10.5	10.5	-
International	4,249	3,879	9.5	13.2	(3.7)	13,194	10,877	21.3	17.5	3.8
	10,346	9,695	6.7	8.2	(1.5)	30,544	26,575	14.9	13.4	1.5
Medical Devices										
U.S.	3,197	3,189	0.3	0.3	-	9,623	9,510	1.2	1.2	-
International	3,390	3,410	(0.6)	3.0	(3.6)	10,703	10,108	5.9	3.2	2.7
	6,587	6,599	(0.2)	1.7	(1.9)	20,326	19,618	3.6	2.2	1.4
U.S.	10,664	10,290	3.6	3.6	-	31,255	29,394	6.3	6.3	-
International	9,684	9,360	3.5	7.5	(4.0)	29,932	26,861	11.4	8.6	2.8
Worldwide	\$ 20,348	19,650	3.6 %	5.5	(1.9)	\$ 61,187	56,255	8.8 %	7.5	1.3

#### Johnson & Johnson and Subsidiaries

##### Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER					NINE MONTHS				
	Percent Change					Percent Change				
	2018	2017	Total	Operations	Currency	2018	2017	Total	Operations	Currency
Sales to customers by geographic area										
U.S.	\$ 10,664	10,290	3.6 %	3.6	-	\$ 31,255	29,394	6.3 %	6.3	-
Europe	4,416	4,308	2.5	5.1	(2.6)	14,023	12,398	13.1	7.1	6.0
Western Hemisphere excluding U.S.	1,550	1,569	(1.2)	11.2	(12.4)	4,657	4,522	3.0	8.4	(5.4)
Asia-Pacific, Africa	3,718	3,483	6.7	8.6	(1.9)	11,252	9,941	13.2	10.8	2.4
International	9,684	9,360	3.5	7.5	(4.0)	29,932	26,861	11.4	8.6	2.8
Worldwide	\$ 20,348	19,650	3.6 %	5.5	(1.9)	\$ 61,187	56,255	8.8 %	7.5	1.3

#### Johnson & Johnson and Subsidiaries

##### Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	THIRD QUARTER				
	2018		2017*		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 20,348	100.0	\$ 19,650	100.0	3.6
Cost of products sold	6,589	32.4	6,925	35.2	(4.9)
Gross Profit	13,759	67.6	12,725	64.8	8.1
Selling, marketing and administrative expenses	5,543	27.3	5,423	27.6	2.2
Research and development expense	2,508	12.3	2,585	13.2	(3.0)
In-process research and development	1,126	5.6	-	-	-
Interest (income) expense, net	68	0.3	155	0.8	-
Other (income) expense, net	3	0.0	(297)	(1.5)	-
Restructuring	88	0.4	69	0.3	-
Earnings before provision for taxes on income	4,423	21.7	4,790	24.4	(7.7)
Provision for taxes on income	489	2.4	1,026	5.2	(52.3)
Net earnings	\$ 3,934	19.3	\$ 3,764	19.2	4.5
Net earnings per share (Diluted)	\$ 1.44		\$ 1.37		5.1
Average shares outstanding (Diluted)	2,727.6		2,737.7		
Effective tax rate	11.1 %		21.4 %		

Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup>					
Earnings before provision for taxes on income	\$ 6,780	33.3	\$ 6,573	33.5	3.1
Net earnings	\$ 5,590	27.5	\$ 5,208	26.5	7.3
Net earnings per share (Diluted)	\$ 2.05		\$ 1.90		7.9
Effective tax rate	17.6 %		20.8 %		

<sup>(1)</sup>See Reconciliation of Non-GAAP Financial Measures.

\*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

#### Johnson & Johnson and Subsidiaries

##### Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	NINE MONTHS				
	2018		2017*		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 61,187	100.0	\$ 56,255	100.0	8.8
Cost of products sold	20,130	32.9	18,180	32.3	10.7
Gross Profit	41,057	67.1	38,075	67.7	7.8
Selling, marketing and administrative expenses	16,549	27.1	15,475	27.5	6.9
Research and development expense	7,551	12.3	6,951	12.4	8.6
In-process research and development	1,126	1.8	-	-	-
Interest (income) expense, net	340	0.6	360	0.6	-
Other (income) expense, net	427	0.7	11	0.0	-
Restructuring	187	0.3	165	0.3	-
Earnings before provision for taxes on income	14,877	24.3	15,113	26.9	(1.6)
Provision for taxes on income	2,622	4.3	3,100	5.5	(15.4)
Net earnings	\$ 12,255	20.0	\$ 12,013	21.4	2.0
Net earnings per share (Diluted)	\$ 4.49		\$ 4.37		2.7
Average shares outstanding (Diluted)	2,729.6		2,746.4		
Effective tax rate	17.6 %		20.5 %		

Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup>

Earnings before provision for taxes on income	\$ 20,652	33.8	\$ 18,961	33.7	8.9
Net earnings	\$ 16,943	27.7	\$ 15,263	27.1	11.0
Net earnings per share (Diluted)	\$ 6.21		\$ 5.56		11.7
Effective tax rate	18.0 %		19.5 %		

(1)See Reconciliation of Non-GAAP Financial Measures.

\*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measures**

(Dollars in Millions Except Per Share Data)	Third Quarter		% Incr. / (Decr.)	Nine Months YTD		% Incr. / (Decr.)
	2018	2017		2018	2017	
Earnings before provision for taxes on income - as reported	\$ 4,423	4,790	(7.7) %	\$ 14,877	15,113	(1.6) %
Intangible asset amortization expense	1,085	1,077		3,284	1,886	
In-process research and development	1,126	-		1,126	-	
Litigation expense, net	-	118		703	611	
Restructuring/Other (1)	190	187		473	476	
Actelion acquisition related cost	40	367		200	580	
Contingent liability reversal	(184)	-		(184)	-	
AMO acquisition related cost	36	36		82	115	
Diabetes asset impairment	-	(2)		4	180	
Unrealized loss/(gain) on securities	9	-		(3)	-	
Other	55	-		90	-	
<b>Earnings before provision for taxes on income - as adjusted</b>	<b>\$ 6,780</b>	<b>6,573</b>	<b>3.1 %</b>	<b>\$ 20,652</b>	<b>18,961</b>	<b>8.9 %</b>
Net Earnings - as reported	\$ 3,934	3,764	4.5 %	\$ 12,255	12,013	2.0 %
Intangible asset amortization expense	968	933		2,931	1,555	
In-process research and development	859	-		859	-	
Litigation expense, net	-	97		609	449	
Restructuring/Other	162	136		395	358	
Actelion acquisition related cost	37	255		193	454	
Contingent liability reversal	(184)	-		(184)	-	
AMO acquisition related cost	29	28		68	314	
Diabetes asset impairment	-	(5)		3	120	
Unrealized loss/(gain) on securities	8	-		(2)	-	
Impact of tax legislation (2)	(265)	-		(253)	-	
Other	42	-		69	-	
<b>Net Earnings - as adjusted</b>	<b>\$ 5,590</b>	<b>5,208</b>	<b>7.3 %</b>	<b>\$ 16,943</b>	<b>15,263</b>	<b>11.0 %</b>
Diluted Net Earnings per share - as reported	\$ 1.44	1.37	5.1 %	\$ 4.49	4.37	2.7 %
Intangible asset amortization expense	0.35	0.34		1.07	0.57	
In-process research and development	0.32	-		0.32	-	
Litigation expense, net	-	0.04		0.22	0.16	
Restructuring/Other	0.06	0.05		0.15	0.14	
Actelion acquisition related cost	0.02	0.09		0.07	0.16	
Contingent liability reversal	(0.07)	-		(0.07)	-	
AMO acquisition related cost	0.01	0.01		0.02	0.11	
Diabetes asset impairment	-	-		-	0.05	
Unrealized loss/(gain) on securities	-	-		-	-	
Impact of tax legislation	(0.10)	-		(0.09)	-	
Other	0.02	-		0.03	-	
<b>Diluted Net Earnings per share - as adjusted</b>	<b>\$ 2.05</b>	<b>1.90</b>	<b>7.9 %</b>	<b>\$ 6.21</b>	<b>5.56</b>	<b>11.7 %</b>
Operational Diluted Net Earnings per share - as adjusted at 2016 foreign currency exchange rates		1.85			5.57	
Impact of currency at 2017 foreign currency exchange rates	0.03	0.05		(0.17)	(0.01)	
<b>Operational Diluted Net Earnings per share - as adjusted at 2017 foreign currency exchange rates</b>	<b>\$ 2.08</b>	<b>1.90</b>	<b>9.5 %</b>	<b>\$ 6.04</b>	<b>5.56</b>	<b>8.6 %</b>

(1)Includes \$23M recorded in cost of products sold and \$79M recorded in other (income) expense for the third quarter 2018. Includes \$73M recorded in cost of products sold and \$213M recorded in other (income) expense for nine months 2018 YTD. Includes \$29M recorded in cost of products sold and \$89M recorded in other (income) expense for the third quarter 2017. Includes \$46M recorded in cost of products sold and \$265M recorded in other (income) expense for nine months 2017 YTD.

(2)Includes foreign currency translation

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measure**

**Operational Sales Growth Excluding Acquisitions and Divestitures**  
**THIRD QUARTER 2018 ACTUAL vs. 2017 ACTUAL**

	Segments			
	Consumer	Pharmaceutical	Medical Devices	Total
	Operational % (1)			
<b>WW As Reported:</b>	<b>4.9%</b>	<b>8.2%</b>	<b>1.7%</b>	<b>5.5%</b>
U.S.	6.6%	4.8%	0.3%	3.6%
International	3.7%	13.2%	3.0%	7.5%
<b>Spine &amp; Other</b>				
<b>Codman Neuroscience</b>			<b>1.0</b>	<b>0.4</b>
U.S.			0.6	0.2
International			1.4	0.5
<b>Wound Care / Other</b>				
<b>Compeed</b>	<b>0.8</b>			<b>0.1</b>
U.S.	0.0			0.0
International	1.3			0.3
<b>Beauty</b>				
<b>Nizoral</b>	<b>0.5</b>			<b>0.1</b>
U.S.	0.3			0.0
International	0.7			0.1
<b>All Other Acquisitions and Divestitures</b>	<b>(0.1)</b>	<b>0.0</b>	<b>0.2</b>	<b>0.0</b>
U.S.	(0.5)	0.0	0.3	0.1
International	0.2	0.0	0.0	0.1

<b>WW Ops excluding Acquisitions and Divestitures</b>	<b>6.1%</b>	<b>8.2%</b>	<b>2.9%</b>	<b>6.1%</b>
U.S.	6.4%	4.8%	1.2%	3.9%
International	5.9%	13.2%	4.4%	8.5%

(1)Operational growth excludes the effect of translational currency

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measure**

**Operational Sales Growth Excluding Acquisitions and Divestitures**  
**NINE MONTHS 2018 ACTUAL vs. 2017 ACTUAL**

	Segments			
	Consumer	Pharmaceutical	Medical Devices	Total
	<b>Operational % (1)</b>			
<b>WW As Reported:</b>	<b>1.9%</b>	<b>13.4%</b>	<b>2.2%</b>	<b>7.5%</b>
U.S.	2.3%	10.5%	1.2%	6.3%
International	1.6%	17.5%	3.2%	8.6%
<b>Pulmonary Hypertension</b>				
<b>Actelion</b>		<b>(4.3)</b>		<b>(2.0)</b>
U.S.		(4.7)		(2.5)
International		(3.8)		(1.6)
<b>Cardiovascular / Metabolism / Other</b>				
<b>Actelion</b>		<b>(0.2)</b>		<b>(0.1)</b>
U.S.		(0.1)		(0.1)
International		(0.3)		(0.1)
<b>Spine &amp; Other</b>				
<b>Codman Neuroscience</b>			<b>1.0</b>	<b>0.4</b>
U.S.			0.6	0.3
International			1.4	0.6
<b>Wound Care / Other</b>				
<b>Compeed</b>	<b>0.9</b>			<b>0.2</b>
U.S.	0.0			0.0
International	1.5			0.3
<b>Vision</b>				
<b>Vision Surgical &amp; Eye Health Business</b>			<b>(1.0)</b>	<b>(0.4)</b>
U.S.			(0.9)	(0.3)
International			(1.1)	(0.4)
<b>Beauty</b>				
<b>Nizoral</b>	<b>0.2</b>			<b>0.0</b>
U.S.	0.1			0.0
International	0.3			0.1
<b>All Other Acquisitions and Divestitures</b>	<b>0.0</b>	<b>0.0</b>	<b>0.1</b>	<b>0.0</b>
U.S.	(0.1)	0.0	0.0	0.0
International	0.2	0.0	0.2	0.1
<b>WW Ops excluding Acquisitions and Divestitures</b>	<b>3.0%</b>	<b>8.9%</b>	<b>2.3%</b>	<b>5.6%</b>
U.S.	2.3%	5.7%	0.9%	3.7%
International	3.6%	13.4%	3.7%	7.6%

(1)Operational growth excludes the effect of translational currency

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**CONSUMER SEGMENT (2)**

**BABY CARE**

**US**

**Intl**

**WW**

**BEAUTY**

**US**

**Intl**

**WW**

**ORAL CARE**

**US**

**Intl**

**WW**

**OTC**

**US**

**Intl**

**WW**

**WOMEN'S HEALTH**

**US**

**Intl**

**WW**

**WOUND CARE / OTHER**

**US**

**Intl**

**WW**

**TOTAL CONSUMER**

**US**

**Intl**

**WW**

	THIRD QUARTER					NINE MONTHS				
	2018	2017	% Change			2018	2017	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
<b>US</b>	\$ 120	\$ 100	20.0%	20.0%	-	\$ 306	\$ 326	-6.1%	-6.1%	-
<b>Intl</b>	352	377	-6.6%	0.1%	-6.7%	1,079	1,100	-1.9%	-0.5%	-1.4%
<b>WW</b>	472	477	-1.0%	4.3%	-5.3%	1,385	1,426	-2.9%	-1.8%	-1.1%
<b>US</b>	543	523	3.8%	3.8%	-	1,791	1,739	3.0%	3.0%	-
<b>Intl</b>	535	510	4.9%	9.2%	-4.3%	1,480	1,351	9.5%	7.7%	1.8%
<b>WW</b>	1,078	1,033	4.4%	6.5%	-2.1%	3,271	3,090	5.9%	5.1%	0.8%
<b>US</b>	158	154	2.6%	2.6%	-	472	460	2.6%	2.6%	-
<b>Intl</b>	226	228	-0.9%	3.6%	-4.5%	684	678	0.9%	-0.5%	1.4%
<b>WW</b>	384	382	0.5%	3.2%	-2.7%	1,156	1,138	1.6%	0.7%	0.9%
<b>US</b>	440	401	9.7%	9.7%	-	1,359	1,310	3.7%	3.7%	-
<b>Intl</b>	608	601	1.2%	4.8%	-3.6%	1,827	1,711	6.8%	3.8%	3.0%
<b>WW</b>	1,048	1,002	4.6%	6.8%	-2.2%	3,186	3,021	5.5%	3.8%	1.7%
<b>US</b>	3	3	0.0%	0.0%	-	10	9	11.1%	11.1%	-
<b>Intl</b>	266	267	-0.4%	8.0%	-8.4%	782	779	0.4%	2.0%	-1.6%
<b>WW</b>	269	270	-0.4%	7.9%	-8.3%	792	788	0.5%	2.1%	-1.6%
<b>US</b>	106	104	1.9%	1.9%	-	344	342	0.6%	0.6%	-
<b>Intl</b>	58	88	-34.1%	-31.3%	-2.8%	183	257	-28.8%	-30.0%	1.2%
<b>WW</b>	164	192	-14.6%	-13.3%	-1.3%	527	599	-12.0%	-12.5%	0.5%
<b>US</b>	1,370	1,285	6.6%	6.6%	-	4,282	4,186	2.3%	2.3%	-
<b>Intl</b>	2,045	2,071	-1.3%	3.7%	-5.0%	6,035	5,876	2.7%	1.6%	1.1%
<b>WW</b>	\$ 3,415	\$ 3,356	1.8%	4.9%	-3.1%	\$ 10,317	\$ 10,062	2.5%	1.9%	0.6%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**PHARMACEUTICAL SEGMENT (2)(5)**

**IMMUNOLOGY**

**US**

**Intl**

	THIRD QUARTER					NINE MONTHS				
	2018	2017	% Change			2018	2017	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
<b>US</b>	\$ 2,400	\$ 2,420	-0.8%	-0.8%	-	\$ 6,717	\$ 6,644	1.1%	1.1%	-
<b>Intl</b>	998	849	17.6%	21.7%	-4.1%	3,061	2,514	21.8%	18.6%	3.2%

WW	3,398	3,269	3.9%	5.0%	-1.1%	9,778	9,158	6.8%	5.9%	0.9%
<b>REMICADE</b>										
US	987	1,206	-18.2%	-18.2%	-	2,821	3,452	-18.3%	-18.3%	-
Intl	100	156	-35.9%	-35.9%	-	346	448	-22.8%	-22.8%	-
WW	292	285	2.5%	8.2%	-5.7%	921	949	-3.0%	-3.9%	0.9%
<b>SIMPONI / SIMPONLARIA</b>	1,379	1,647	-16.3%	-15.3%	-1.0%	4,088	4,849	-15.7%	-15.9%	0.2%
US	281	242	16.1%	16.1%	-	779	701	11.1%	11.1%	-
Intl	255	234	9.0%	13.5%	-4.5%	823	642	28.2%	25.3%	2.9%
WW	536	476	12.6%	14.8%	-2.2%	1,602	1,343	19.3%	17.9%	1.4%
<b>STELARA</b>										
US	889	800	11.1%	11.1%	-	2,460	2,027	21.4%	21.4%	-
Intl	421	324	29.9%	33.0%	-3.1%	1,252	903	38.6%	32.9%	5.7%
WW	1,310	1,124	16.5%	17.4%	-0.9%	3,712	2,930	26.7%	24.9%	1.8%
<b>OTHER IMMUNOLOGY</b>										
US	143	16	*	*	-	311	16	*	*	-
Intl	30	6	*	*	*	65	20	*	*	*
WW	173	22	*	*	*	376	36	*	*	*
<b>INFECTIOUS DISEASES</b>										
US	345	353	-2.3%	-2.3%	-	1,006	1,020	-1.4%	-1.4%	-
Intl	478	460	3.9%	7.4%	-3.5%	1,496	1,334	12.1%	8.1%	4.0%
WW	823	813	1.2%	3.2%	-2.0%	2,502	2,354	6.3%	4.0%	2.3%
<b>EDURANT / rilpivirine</b>										
US	13	15	-13.3%	-13.3%	-	42	44	-4.5%	-4.5%	-
Intl	189	179	5.6%	6.8%	-1.2%	581	478	21.5%	14.2%	7.3%
WW	202	194	4.1%	5.2%	-1.1%	623	522	19.3%	12.6%	6.7%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>										
US	297	287	3.5%	3.5%	-	847	824	2.8%	2.8%	-
Intl	193	180	7.2%	12.4%	-5.2%	613	527	16.3%	13.5%	2.8%
WW	490	467	4.9%	6.9%	-2.0%	1,460	1,351	8.1%	7.0%	1.1%
<b>OTHER INFECTIOUS DISEASES</b>										
US	35	51	-31.4%	-31.4%	-	117	152	-23.0%	-23.0%	-
Intl	96	101	-5.0%	-0.3%	-4.7%	302	329	-8.2%	-9.3%	1.1%
WW	131	152	-13.8%	-10.7%	-3.1%	419	481	-12.9%	-13.7%	0.8%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	THIRD QUARTER					NINE MONTHS				
	2018	2017	% Change			2018	2017	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>NEUROSCIENCE</b>										
US	651	647	0.6%	0.6%	-	1,914	1,931	-0.9%	-0.9%	-
Intl	839	851	-1.4%	2.1%	-3.5%	2,663	2,531	5.2%	2.3%	2.9%
WW	1,490	1,498	-0.5%	1.5%	-2.0%	4,577	4,462	2.6%	0.9%	1.7%
<b>CONCERTA / methamphetamine</b>										
US	57	100	-43.0%	-43.0%	-	191	284	-32.7%	-32.7%	-
Intl	100	98	2.0%	7.3%	-5.3%	322	304	5.9%	4.4%	1.5%
WW	157	198	-20.7%	-18.1%	-2.6%	513	588	-12.8%	-13.6%	0.8%
<b>INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA</b>										
US	468	395	18.5%	18.5%	-	1,306	1,154	13.2%	13.2%	-
Intl	281	248	13.3%	16.6%	-3.3%	859	722	19.0%	14.2%	4.8%
WW	749	643	16.5%	17.8%	-1.3%	2,165	1,876	15.4%	13.5%	1.9%
<b>RISPERDAL CONSTA</b>										
US	76	87	-12.6%	-12.6%	-	238	273	-12.8%	-12.8%	-
Intl	99	107	-7.5%	-4.0%	-3.5%	321	335	-4.2%	-7.3%	3.1%
WW	175	194	-9.8%	-7.9%	-1.9%	559	608	-8.1%	-9.8%	1.7%
<b>OTHER NEUROSCIENCE</b>										
US	50	65	-23.1%	-23.1%	-	179	220	-18.6%	-18.6%	-
Intl	359	398	-9.8%	-6.6%	-3.2%	1,161	1,170	-0.8%	-2.9%	2.1%
WW	409	463	-11.7%	-9.0%	-2.7%	1,340	1,390	-3.6%	-5.4%	1.8%
<b>ONCOLOGY</b>										
US	1,250	846	47.8%	47.8%	-	3,268	2,207	48.1%	48.1%	-
Intl	1,338	1,052	27.2%	31.2%	-4.0%	4,087	3,012	35.7%	30.9%	4.8%
WW	2,588	1,898	36.4%	38.6%	-2.2%	7,355	5,219	40.9%	38.1%	2.8%
<b>DARZALEX</b>										
US	318	230	38.3%	38.3%	-	880	643	36.9%	36.9%	-
Intl	180	87	*	*	*	561	228	*	*	*
WW	498	317	57.1%	60.0%	-2.9%	1,441	871	65.4%	63.6%	1.8%
<b>IMBRUVICA</b>										
US	334	230	45.2%	45.2%	-	811	622	30.4%	30.4%	-
Intl	371	282	31.6%	36.6%	-5.0%	1,101	749	47.0%	42.2%	4.8%
WW	705	512	37.7%	40.4%	-2.7%	1,912	1,371	39.5%	36.9%	2.6%
<b>VELCADE</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	271	273	-0.7%	1.8%	-2.5%	864	843	2.5%	-1.7%	4.2%
WW	271	273	-0.7%	1.8%	-2.5%	864	843	2.5%	-1.7%	4.2%
<b>ZYTIGA</b>										
US	527	352	49.7%	49.7%	-	1,420	826	71.9%	71.9%	-
Intl	431	317	36.0%	38.8%	-2.8%	1,292	924	39.8%	34.2%	5.6%
WW	958	669	43.2%	44.5%	-1.3%	2,712	1,750	55.0%	52.0%	3.0%
<b>OTHER ONCOLOGY</b>										
US	71	34	*	*	-	157	116	35.3%	35.3%	-
Intl	85	93	-8.6%	-4.7%	-3.9%	269	268	0.4%	-2.5%	2.9%
WW	156	127	22.8%	25.6%	-2.8%	426	384	10.9%	8.9%	2.0%
<b>PULMONARY HYPERTENSION<sup>(4)</sup></b>										
US	425	371	14.6%	14.6%	-	1,215	408	*	*	-
Intl	231	261	-11.5%	-8.9%	-2.6%	691	309	*	*	*
WW	656	632	3.8%	4.9%	-1.1%	1,906	717	*	*	*
<b>QPSUMIT</b>										
US	182	150	21.3%	21.3%	-	511	174	*	*	-
Intl	128	109	17.4%	20.9%	-3.5%	381	130	*	*	*
WW	310	259	19.7%	21.2%	-1.5%	892	304	*	*	*
<b>TRACLEER</b>										
US	69	83	-16.9%	-16.9%	-	208	85	*	*	-
Intl	70	127	-44.9%	-43.6%	-1.3%	214	151	41.7%	37.5%	4.2%
WW	139	210	-33.8%	-33.0%	-0.8%	422	236	78.8%	76.1%	2.7%
<b>UPTRAVI</b>										
US	154	113	36.3%	36.3%	-	433	121	*	*	-
Intl	17	11	54.5%	57.3%	-2.8%	49	12	*	*	*
WW	171	124	37.9%	38.1%	-0.2%	482	133	*	*	*
<b>OTHER</b>										
US	20	25	-20.0%	-20.0%	-	63	28	*	*	-
Intl	16	14	14.3%	21.2%	-6.9%	47	16	*	*	*
WW	36	39	-7.7%	-5.2%	-2.5%	110	44	*	*	*
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>										
US	1,026	1,179	-13.0%	-13.0%	-	3,230	3,488	-7.4%	-7.4%	-
Intl	365	406	-10.1%	-6.5%	-3.6%	1,196	1,177	1.6%	-1.1%	2.7%
WW	1,391	1,585	-12.2%	-11.3%	-0.9%	4,426	4,665	-5.1%	-5.8%	0.7%
<b>XARELTO</b>										
US	612	635	-3.6%	-3.6%	-	1,869	1,790	4.4%	4.4%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	612	635	-3.6%	-3.6%	-	1,869	1,790	4.4%	4.4%	-



 View original content to download multimedia:<http://www.prnewswire.com/news-releases/johnson-johnson-reports-2018-third-quarter-results-300731779.html>

SOURCE Johnson & Johnson

News Provided by Acquire Media